Update in renal transplantation

Archives of Internal Medicine

Volumn 164, Issue 13, 2004, Pages 1373-1388

  Magee, Colm C ^a   Pascual, Manuel ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE GRAFT REJECTION; BONE DISEASE; BONE MARROW SUPPRESSION; BONE NECROSIS; CARDIOVASCULAR DISEASE; CYTOMEGALOVIRUS INFECTION; DEATH; DIABETES MELLITUS; DIARRHEA; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; GRAFT SURVIVAL; GROWTH RETARDATION; HEPATITIS; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVING DONOR; MYOPATHY; NAUSEA; NEPHROTOXICITY; ORGAN DONOR; OSTEOPOROSIS; PANCREATITIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECIPIENT; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIBODY FORMATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME; UNITED STATES;

EID: 3142763829     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.13.1373     Document Type: Review

References (130)

1. Cameron JI, Whiteside C, Katz J, Devins GM. Differences in quality of life across renal replacement therapies: a meta-analytic comparison. Am J Kidney Dis. 2000;35:629-637.
2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725-1730.
3. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50:235-242.
4. US Renal Data System. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2002.
5. Gjertson DW. Impact of delayed graft function and acute rejection on kidney graft survival. Clin Transpl. 2000:467-480.
6. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2001;12:848-855.
7. Cecka JM. The UNOS renal transplant registry. Clin Transpl. 2001:1-18.
8. Claas FH. Towards clinical transplantation tolerance. Lancet. 2003;361:1489-1490.
9. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003;361:1502-1510.
10. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999;353:1083-1091.
11. Nishikawa K, Terasaki PI. Annual trends and triple therapy: 1991-2000. Clin Transpl. 2001:247-269.
12. Hricik D. Steroid-free immunosuppression in kidney transplantation: an editorial review. Am J Transplant. 2002;2:19-24.
13. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of neoral C(2) monitoring: a review. Transplantation. 2002;73(suppl):S3-S11.
14. Internation Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant. 2002;2:157-166.
15. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73:775-782.
16. Takemoto SK. Maintenance immunosuppression. Clin Transpl. 2001:223-236.
17. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580-590.
18. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C, for the International Mycophenolate Mofetil Renal Transplant Study Groups. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation. 1997;63:39-47.
19. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation. 2000;69:2405-2409.
20. Hubner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit. 1999;21:536-539.
21. Halloran PF. Sirolimus and cyclosporin for renal transplantation. Lancet. 2000;356:179-180.
22. Kahan BD, for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet. 2000;356:194-202.
23. Vincenti F. What's in the pipeline? new immunosuppressive drugs in transplantation. Am J Transplant. 2002;2:898-903.
24. Salama AD, Remuzzi G, Harmon WE, Sayegh MH. Challenges to achieving clinical transplantation tolerance. J Clin Invest. 2001;108:943-948.
25. Gourishankar S, Turner P, Halloran P. New developments in immunosuppressive therapy in renal transplantation. Expert Opin Biol Ther. 2002;2:483-501.
26. Swanson SJ, Hale DA, Mannon RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet. 2002;360:1662-1664.
27. Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol. 2002;13:2145-2151.
28. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant. 2002;2:993-998.
29. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol. 1999;10:2208-2214.
30. Montgomery R, Zachary A, Racusen L, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70:887-895.
31. Pascual M, Saidman S, Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation. 1998;66:1460-1464.
32. Vella JP, O'Neill D, Atkins N, Donohoe JF, Walshe JJ. Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrol Dial Transplant. 1998;13:2027-2032.
33. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation. 2000;70:1531-1536.
34. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulin (IVIg). Am J Transplant. 2002;2:691-692.
35. Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med. 2001;344:726-731.
36. US Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients. US Organ Donors by Organ and Donor Type, 1993 to 2002. Available at: http//:www.optn.org/AR2003/101_dh.pdf. Accessed May 5, 2004.
37. Gjertson DW, Cecka JM. Living unrelated donor kidney transplantation. Kidney Int. 2000;58:491-499.
38. Finelli FC, Gongora E, Sasaki TM, Light JA. A survey: the prevalence of laparoscopic donor nephrectomy at large US transplant centers. Transplantation. 2001;71:1862-1864.
39. Schweitzer EJ, Wilson J, Jacobs S, et al. Increased rates of donation with laparoscopic donor nephrectomy. Ann Surg. 2000;232:392-400.
40. Novick AC. Laparoscopic live donor nephrectomy: con. Urology. 1999;53:668-670.
41. Wolf JS Jr, Merion RM, Leichtman AB, et al. Randomized controlled trial of hand-assisted laparoscopic versus open surgical live donor nephrectomy. Transplantation. 2001;72:284-290.
42. British Transplant Society. UK Guidelines for Living Donor Kidney Donation. London, England: British Transplant Society; 2000:9-14.
43. Kasiske BL, Ravenscraft M, Ramos EL, Gaston RS, Bia MJ, Danovitch GM, for the Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians. The evaluation of living renal transplant donors: clinical practice guidelines. J Am Soc Nephrol. 1996;7:2288-2313.
44. Fehrman-Ekholm I, Elinder CG, Stenbeck M, Tyden G, Groth CG. Kidney donors live longer. Transplantation. 1997;64:976-978.
45. Ellison MD, McBride MA, Taranto SE, Delmonico FL, Kauffman HM. Living kidney donors in need of kidney transplants: a report from the organ procurement and transplantation network. Transplantation. 2002;74:1349-1351.
46. Hakim RM, Goldszer RC, Brenner BM. Hypertension and proteinuria: long-term sequelae of uninephrectomy in humans. Kidney Int. 1984;25:930-936.
47. Gridelli B, Remuzzi G. Strategies for making more organs available for transplantation. N Engl J Med. 2000;343:404-410.
48. Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol. 2001;12:589-597.
49. Cecka JM. Donors without a heartbeat. N Engl J Med. 2002;347:281-283.
50. Weber M, Dindo D, Demartines N, Ambuhl PM, Clavien PA. Kidney transplantation from donors without a heartbeat. N Engl J Med. 2002;347:248-255.
51. Rudich SM, Kaplan B, Magee JC, et al. Renal transplantations performed using non-heart-beating organ donors: going back to the future? Transplantation. 2002;74:1715-1720.
52. Vanrenterghem Y. Cautious approach to use of non-heart-beating donors. Lancet. 2000;356:528.
53. Lopez-Navidad A, Caballero F, Domingo P, Esperalba J, Viedma MA. Hospital professionalization of the organ procurement process maximizes the retrieval potential. Transplant Proc. 1999;31:1039.
54. Rosendale JD, Chabalewski FL, McBride MA, et al. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant. 2002;2:761-768.
55. Radcliffe-Richards J, Daar AS, Guttmann RD, et al, for the International Forum for Transplant Ethics. The case for allowing kidney sales. Lancet. 1998;351:1950-1952.
56. Dorling A. Clinical xenotransplantation: pigs might fly? Am J Transplant. 2002;2:695-700.
57. Collignon P. Xenotransplantation trials. Lancet. 2002;359:2281.
58. Fishman JA. Infection in xenotransplantation. BMJ. 2000;321:717-718.
59. Platt J, DiSesa V, Gail D, Massicot-Fisher J. Recommendations of the National Heart, Lung, and Blood Institute Heart and Lung Xenotransplantation Working Group. Circulation. 2002;106:1043-7.
60. Cameron JS. Renal transplantation in the elderly. Int Urol Nephrol. 2000;32:193-201.
61. Johnson DW, Herzig K, Purdie D, et al. A comparison of the effects of dialysis and renal transplantation on the survival of older uremic patients. Transplantation. 2000;69:794-799.
62. Kasiske BL, Snyder J. Matching older kidneys with older patients does not improve allograft survival. J Am Soc Nephrol. 2002;13:1067-1072.
63. Epstein AM, Ayanian JZ, Keogh JH, et al. Racial disparities in access to renal transplantation: clinically appropriate or due to underuse or overuse? N Engl J Med. 2000;343:1537-1544. 2 p preceding 1537.
64. Furth SL, Garg PP, Neu AM, Hwang W, Fivush BA, Powe NR. Racial differences in access to the kidney transplant waiting list for children and adolescents with end-stage renal disease. Pediatrics. 2000;106:756-761.
65. Young CJ, Gaston RS. Renal transplantation in black Americans. N Engl J Med. 2000;343:1545-1552.
66. Rosendale JD, McBride MA, Davies DB. Organ donation in the United States: 1988-2000. Clin Transpl. 2001:87-96.
67. Wolfe RA, Ashby VB, Milford EL, et al. Differences in access to cadaveric renal transplantation in the United States. Am J Kidney Dis. 2000;36:1025-1033.
68. Levinsky NG. Quality and equity in dialysis and renal transplantation. N Engl J Med. 1999;341:1691-1693.
69. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999;341:1198-1205.
70. Foster CE III, Philosophe B, Schweitzer EJ, et al. A decade of experience with renal transplantation in African-Americans. Ann Surg. 2002;236:794-804.
71. Mitka M. Change in kidney transplantation priority will help organ recipients in the minority. JAMA. 2002;288:2953.
72. Neylan JF, for the FK506 Kidney Transplant Study Group. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation. 1998;65:515-523.
73. Neylan JF, for the US Renal Transplant Mycophenolate Mofetil Study Group. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation. 1997;64:1277-1282.
74. Cecka JM. The UNOS Scientific Renal Transplant Registry: 2000. Clin Transpl. 2000:1-18.
75. Gow PJ, Pillay D, Mutimer D. Solid organ transplantation in patients with HIV infection. Transplantation. 2001;72:177-181.
76. Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-187.
77. Cecka JM. The UNOS Scientific Renal Transplant Registry. Clin Transpl. 1999:1-21.
78. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant. 2001;16:1545-1549.
79. Kasiske BL, Vazquez MA, Harmon WE, et al, for the American Society of Transplantation. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol. 2000;11(suppl 15):S1-S86.
80. Sung RS, Althoen M, Howell TA, Ojo AO, Merion RM. Excess risk of renal allograft loss associated with cigarette smoking. Transplantation. 2001;71:1752-1757.
81. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol. 2002;13:1084-1090
82. Rigatto C. Clinical epidemiology of cardiac disease in renal transplant recipients. Semin Dial. 2003;16:106-110.
83. Opelz G, Wujciak T, Ritz E, for the Collaborative Transplant Study. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int. 1998;53:217-222.
84. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
85. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
86. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446 [published correction appears in Arch Intern Med. 1998;158:573].
87. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446 [published correction appears in Arch Intern Med. 1998;158:573].
88. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA. 1998;279:1813-1816.
89. Holdaas H, Fellstrom B, Jardine A, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024-2031.
90. Bae J, Jarcho JA, Denton MD, Magee CC. Statin specific toxicity in organ transplant recipients: case report and review of the literature. J Nephrol. 2002;15:317-319.
91. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol. 2000;11:134-137.
92. Kewalramani R, Winkelmayer W, Rutstein M, et al. Anemia in renal transplant recipients: an emerging concern. In: American Transplant Congress. Washington, DC: American Society of Transplantation; 2003.
93. Lorenz M, Kletzmayr J, Perschl A, Furrer A, Horl WH, Sunder-Plassmann G. Anemia and iron deficiencies among long-term renal transplant recipients. J Am Soc Nephrol. 2002;13:794-797.
94. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol. 2003;14:462-468.
95. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification: Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002; 39(2, suppl 2):S17-S31.
96. Thomas MC, Mathew TH, Russ GR. Glycaemic control and graft loss following renal transplantation. Nephrol Dial Transplant. 2001;16:1978-1982.
97. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 2002;25:583-592.
98. Baid S, Tolkoff-Rubin N, Farrell ML, et al. Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: role of hepatitis C infection. Transplant Proc. 2002;34:1771-1773.
99. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002;13:1374-1380.
100. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
101. Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. Arch Intern Med. 2003;163:33-40.
102. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) cases reported to the United Network for Organ Sharing (UNOS) and non-US cases reported to the International Pancreas Transplant Registry (IPTR) as of October, 2000. Clin Transpl. 2000:45-72.
103. Hariharan S, Pirsch JD, Lu CY, et al. Pancreas after kidney transplantation. J Am Soc Nephrol. 2002;13:1109-1118.
104. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation. 2001;71:82-90.
105. La Rocca E, Fiorina P, di Carlo V, et al. Cardiovascular outcomes after kidney-pancreas and kidney-alone transplantation. Kidney Int. 2001;60:1964-1971.
106. Manske CL. Risks and benefits of kidney and pancreas transplantation for diabetic patients. Diabetes Care. 1999;22(suppl 2):B114-B120.
107. Markmann JF, Campos L, Velidedeoglu E, et al. Annual literature review: clinical transplants 2000. Clin Transpl. 2000:411-465.
108. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230-238.
109. Penn I. Posttransplant malignancies. Transplant Proc. 1999;31:1260-1262.
110. Chapman J, Webster A. Chapter 10: Cancer Report. In: 2002 Report of the ANZDATA Registry. Adelaide, South Australia: ANZDATA Registry; 2002. Available at: http://www.anzdata.org.au/ANZDATA/AnzdataReport/report.htm. Accessed May 19, 2004.
111. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397:530-534.
112. Jemec GB, Holm EA. Nonmelanoma skin cancer in organ transplant patients. Transplantation. 2003;75:253-257.
113. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation: section IV: long-term management of the transplant recipient. IV.6.2. cancer risk after renal transplantation, skin cancers: prevention and treatment. Nephrol Dial Transplant. 2002;17(suppl 4):31-36.
114. Penn I. Neoplastic complications of transplantation. Semin Respir Infect. 1993;8:233-239.
115. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation. 2001;71:1065-1068.
116. Meijer E, Dekker AW, Weersink AJ, Rozenberg-Arska M, Verdonck LF. Prevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants. Br J Haematol. 2002;119:596-607.
117. Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol. 2002;118:728-740.
118. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741-1751.
119. Rubin RH. Cytomegalovirus in solid organ transplantation. Clin Infect Dis. 2001;39(suppl):S1-S5.
120. Kusne S, Shapiro R, Fung J. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis. 1999;1:187-203.
121. Lowance D, Neumayer HH, Legendre CM, et al, for the International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med. 1999;340:1462-1470.
122. Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA. 2001;286:2450-2460.
123. Stark K, Gunther M, Schonfeld C, Tullius SG, Bienzle U. Immunisations in solid-organ transplant recipients. Lancet. 2002;359:957-965.
124. Delmas PD. Osteoporosis in patients with organ transplants: a neglected problem. Lancet. 2001;357:325-326.
125. Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation. 1994;58:912-915.
126. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol. 2002;13:551-558.
127. Weber TJ, Quarles LD. Preventing bone loss after renal transplantation with bisphosphonates: we can, but should we? Kidney Int. 2000;57:735-737.
128. Grotz W, Nagel C, Poeschel D, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001;12:1530-1537.
129. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12:1164-1172.
130. Heaf JG. Bone disease after renal transplantation. Transplantation. 2003;75:315-325.